Clinical Trials Logo
  1. Home
  2. Hepatobiliary Neoplasm
  3. NCT06049836

Holographic Augmented Reality Versus Screen Visualisation of 3D Rendering Models for the Pre-operative Evaluation and Planning of Liver Resections

Hepatobiliary Neoplasm Clinical Trial

Official title:
Holographic Augmented Reality Versus Screen Visualisation of 3D Rendering Models for the Pre-operative Evaluation and Planning of Liver Resections

Clinical Trial Summary

The goal of this trial is to compare the evaluation of 3D liver models visualised as holograms with HoloLens 2 and on digital PDF files in HPB surgical trainees. The main questions it aims to answer are: - Do the holographic models allow a superior accuracy in terms of anatomical evaluation and surgical planning? - Is there any difference in terms of time consumed and Task Load Index? Participants will analyse cases through both modalities and answer a questionnaire.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06049836
Study type Interventional
Source Federico II University
Contact
Status Completed
Phase N/A
Start date October 15, 2023
Completion date February 1, 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01020812 - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma Phase 1/Phase 2
Completed NCT04959630 - Immersive Virtual Reality Environment for Complex Cognitive Skills Curricular Training in Liver Surgery N/A
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Recruiting NCT04010071 - Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors Phase 2
Recruiting NCT04709445 - Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses N/A
Terminated NCT01151761 - PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation Phase 2
Active, not recruiting NCT04501913 - Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
Withdrawn NCT03818997 - Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer Phase 2
Completed NCT04642664 - Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer Phase 2
Not yet recruiting NCT03760289 - DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer Phase 2
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A